![]() | Only 14 pages are availabe for public view |
Abstract Acute myeloid leukemia is a diverse medical condition distinguished by various abnormalities in genetics and variable morphology, immunophenotypes, and clinical outcomes. It is the commonest leukemia in adults, accounting for 25% of all leukemia types. French-American-British (FAB) classification had been utilised to diagnose and subtype AML. Which was ascertained that many cases were correlated with repetitive abnormalities in genetics involved with pathways of myeloid cell proliferation/maturation. In 2017, a newly revised classification of myeloid neoplasms and acute leukemias, that correlates clinical characteristics, morphology, immunophenotyping, cytogenetics, and molecular genetics to describe disease entities with more significance clinically was published by the WHO. Immunophenotyping renders itself a crucial means used in the diagnosis and subcategorization of hematological neoplasms. It has provided essential and pivotal information for the management of leukemias. In patients with AML with monocytic differentiation presenting with overt signs or symptoms of neurological involvement at initial diagnosis, relevant scanning to detect meningeal disease, chloromas, or CNS bleeding is advised. However, if no lesion is picked up, lumbar puncture (LP) should be undertaken. Screening LP is to be contemplated at first remission prior to the start of a first consolidation therapy commenced for patient. More importantly, giving the patient one dose of intrathecal (IT) chemotherapy (methotrexate or cytarabine) should be considered at same timeframe of post induction LP. In an attempt to better characterize the positivity of expression of monocytic markers ROC curves were plotted to assess whether or not a cutoff value can be determined for each of the monocytic markers used in our AML panel. The Mean Fluorescence Intensity (MFI) of patients with percentage expresion equal to or more than 20% were plotted and this resulted in the figures below. |